Routine vaccines can cut risk for later Alzheimer’s disease
Aug 23, 2023
The findings were seen for tetanus and diphtheria, shingles and pneumococcus vaccines.
Staffing shortage top issue facing CNAs on the job: survey
By
Kathleen Steele Gaivin
Jul 28, 2023
A continued staffing shortage is the prime issue facing certified nursing assistants for the second year in a row, according to the results of a survey released Wednesday at CNA Fest in Little Rock, AR.
Instrumental activities of daily living test could ID Alzheimer’s disease
Jun 28, 2023
An association was found between simulated real-life IADL and interactions of amyloid and early tau accumulation in cognitively normal seniors.
Gut microbial taxonomic profiles differ with, without preclinical Alzheimer’s disease
Jun 16, 2023
A change in gut microbiome composition was associated with β-amyloid and tau pathological brain biomarkers.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
Insurance company argues against defending senior living operator in wrongful death suit
By
Kimberly Bonvissuto
Jan 18, 2023
A policy lapse means that an insurer does not have to defend an assisted living community from a wrongful death lawsuit, the insurer is arguing in federal court.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Study explores impact of FDA approval of aducanumab on trial participation
Dec 06, 2022
Individuals who were independently aware of the FDA decision demonstrated a reduced willingness to participate.
Racial/ethnic minorities underrepresented in Alzheimer’s neuroimaging research
Jul 28, 2023
Sample diversity has improved recently, with proportion of Blacks increasing from 3.39% in 1994-2017 to 8.29% in 2018-2022.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.